In addition to CXCR3 antagonists, a neutralizing CXCL10 antibody, MDX-1100, is also being tested by Medarex for the treatment of rheumatoid arthritis and is currently in clinical phase II studies (Yellin et al., 2012). This evidence concerns the gene CXCR3 and rheumatoid arthritis.